Mylan 3Q profit up 15 percent on generic sales

Oct 30 - Mylan Inc. said Thursday its third-quarter profit grew 15 percent due to sales from the Merck KGaA generic business, which it bought last year, and deferred revenue from the sale of a blood pressure drug.

Net income rose to $172 million, or 45 cents a share, from $149.8 million, or 60 cents a share, a year earlier. Excluding one-time gains, Mylan said its profit was $105.4 million, or 23 cents per share still much larger than analysts expected. Revenue more than tripled to $1.66 billion from $477.1 million a year ago. Most of that gain came from the Merck KGaA generic business, which Mylan bought in October 2007. Mylan gained $687.2 million in revenue from the Merck KGaA generic unit, which gave the company entry into the markets of Europe, the Middle East, Africa, and the Asia-Pacific region. It recognized $455 million in deferred revenue from the Bystolic sale.

Analysts Expectation:
Analysts expected a profit of 11 cents per share on $1.15 billion in revenue, according to Thomson Reuters. Those estimates typically exclude one-time items.

Full Year Outlook: Raised
The generic drug maker boosted its outlook for 2008, in part based on strong sales of its fentanyl pain product. It affirmed its outlook for the next two years. Mylan increased its full-year earnings-per-share forecast, excluding items, to a range of 64 cents to 67 cents, from a prior outlook of 47 cents to 53 cents.

Reaction of the Earnings:
Mylan shares were up $1.52, or 21.8 percent, at $8.50 in early New York Stock Exchange trading.

Third-quarter Earning of Eli Lilly and Co.

Oct 23, Eli Lilly and Co. said an expected settlement of investigations into top-selling drug Zyprexa wiped out its third-quarter profit, but the drugmaker's adjusted earnings still beat Wall Street expectations.

Eli Lilly lost $465.6 million, or 43 cents per share. Last year it earned $926.3 million, or 85 cents per share, in the same quarter. Excluding charges that included almost $1.5 billion for the settlement, Lilly earned $1.04 per share. Sales climbed 14 percent to $5.21 billion from $4.59 billion. Lilly saw overall sales volume grow 6 percent in the quarter, driven by big increases for several products. Sales for the anti-psychotic Zyprexa rose 2 percent to $1.19 billion.

Analysts’ Expectation:
Thomson Reuters says analysts were expecting a profit of $1.02 per share and revenue of $5.09 billion, excluding the payment.

Full Year’s Earning Forecast:
Based on the third-quarter results, Lilly raised its adjusted profit forecast to $3.97 to $4.02 per share, up from $3.85 to $4 per share. Including the Zyprexa settlement, however, the company now expects a profit of $2.44 to $2.49 per share - down from $3.79 to $3.94 per share. Analysts expected a profit of $3.95 per share on $20.55 billion in revenue. On Oct. 6, Lilly agreed to buy ImClone accepted for more than $6 billion, or $70 per share.

Reaction of the Earning:
The company's stock price rose 2 percent, or 64 cents, in Thursday morning trading to $32.75 and at the end of the day it rose more than 4%.

Shah added in his Portfolio: Merck & Co. Inc. (MRK)

Shah added to his holdings in Merck & Co. Inc. by 40.73%. The impact to his portfolio due to this purchase was 1.04%. His holdings were 22,371,200 shares as of 09/30/2008.
Merck & Co. Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891 Merck discovers develops manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. Merck & Co. Inc. has a market cap of $64.68 billion; its shares were traded at around $28.68 with a P/E ratio of 14.45 and P/S ratio of 2.55. The dividend yield of Merck & Co. Inc. stocks is 5.33%.

Abbott Laboratories reported 18% Revenue increased raising their Full Year Outlook

In October 15, Abbott Laboratories reported a net income of 1.084 billion or $0.69 per share compared to $717.005 million or $0.46 per share last year.

Excluding specified items net income came in at $1.235 billion or $0.79 per share compared to $1.046 billion or $0.67 per share a year ago. On average, 14 analysts polled by First Call/Thomson Financial expected the company to earn $0.77 per share. Gross margin inched up to 55.3% from 55.1%. Revenue overall rose 18 percent to $7.5 billion. Worldwide sales increased 17.6% $7.497 billion, including a favorable 4.7% effect of exchange rates, compared to $6.377 billion in the prior year. Analysts were looking for $7.35 billion.

Outlook:

The company raised its outlook full-year 2008 to $3.31 - $3.33 per share from $3.24 - $3.28 per share, excluding specified items. Abbott reaffirmed the net specified items for the full-year 2008 of $0.08 per share, primarily associated with cost reduction initiatives and acquired in-process R&D. Including the specified items, projected earnings per share under GAAP would be $3.23 - $3.25 for the full-year 2008.

Abbott's original guidance range for 2008, provided in January, was $3.20 - $3.25. Wall Street was expecting $3.28 per share, with estimates in the range of $3.21-$3.30 per share.

Johnson & Johnson in 14 October reported a 30% jump in third-quarter profit

Health care giant Johnson & Johnson in 14 October reported a 30% jump in third-quarter profit, beating Wall Street expectations, due to higher sales of consumer products and medical devices and a large restructuring charge a year ago.

JNJ earned $3.31 billion or $1.17 per share in the quarter compared with $2.55 billion, or 88 cents per share, in the year-earlier period, when the company took restructuring charges. Revenue climbed 6.3%, to $15.9 billion from $14.97 billion. Quarterly sales rose 6.4% to $15.92 billion, somewhat higher than the Reuters Estimates forecast of $15.71 billion. Sales of consumer products, which range from Band-Aids to Listerine mouthwash, rose 13.1% to $4.1 billion. Medical device sales rose 8.8% to $5.71 billion, although sales of the company's Cypher drug-coated stent fell more than 20% to $289 million due to competition. Prescription drug sales edged up 0.2% to $6.11 billion, was hurt by the U.S. patent expiration in June.

Analysts Expectation:

Analysts surveyed by Thomson Financial expected earnings per share of $1.11 and revenue of $15.69 billion. Jan Wald, an analyst with Stanford Group Co, said J&J posted solid results thanks largely to its diversified nature, although he does not expect its pharmaceuticals sales to greatly improve for another two to three years -- after new products are approved.

Full Year Outlook: Raised

Johnson & Johnson raised its full-year profit forecast to $4.50 to $4.53 per share, excluding one-time charges and other items. During the last quarter, it had forecast a profit of $4.45 to $4.50 a share.

For the first nine months, net income jumped 25%, to $10.24 billion, or $3.60 per share, up from $8.2 billion, or $2.81 per share. Revenue was up 7.6%, to $48.57 billion from $45.14 billion.

Reaction of the Earnings:

Shares of J&J rose 5.9 percent to $66.40 in morning trading on the New York Stock Exchange.

DSE came back with the sweet sound of Bank Sector

News by stock mania analyst Shah/Bang/chart.http://www.dsebd.org/ DSE and CSE is coming out from their deepest sock after a long run over. AB Bank with its new hit reached tthe yeard of one thousand boundary. Technically MACD made a strong long run Convergence that along with other indicators shoed near destination around fifteen hundred. He maintained his ratings Buy as usual Hold citing fundamental stability.
All "a" class banks are on the rally of upwards trend. So, he maintained Hold ratings on the Bank sector. Among the groups he kept first and foremost choice on Beximco group. All other sector of DSE and CSE are in the negative territory said in his reaserch note today afternoon in his press room.

Barr Announces Approval of Generic Aredia(R) Injection, 30mg/mL, 60mg/mL and 90mg/mL Injectable

Barr Pharmaceuticals Inc
News, chart, profile, more
Last: 67.39-0.35-0.52%4:03pm 08/21/2008Delayed quote data
Add to portfolioAnalyst Create alert
InsiderDiscussFinancials
Sponsored by:
BRL 67.39, -0.35, -0.5%) today announced that its subsidiary, PLIVA - Lachema a.s., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pfizer Inc.'s Aredia(R) (pamindronate disodium) Injection, 30mg/mL, 60mg/mL, and 90mg/mL. The Company plans to launch its product in the fourth quarter of calendar 2008. With this approval, Barr's U.S. generic injectable portfolio now totals eight products.

Barr's generic Aredia (pamindronate disodium) product will compete in a market that had total annual sales of approximately $21 million for the twelve months ended June 2008, based on IMS sales data, wrote in his research note Stock Mania analyst Shah.

Pain Thera/King Pharma say Phase III data shows Remoxy pain drug effective

BOSTON (Shah, analyst LSE and Stock Mania) - Pain Therapeutics Inc. and King Pharmaceuticals Inc. Thursday said final data from their Phase III study of Remoxy, an investigational drug to treat chronic pain, showed the drug was effective in providing around-the-clock analgesia within a patented formulation designed to resist common methods of misuse and abuse.
The companies said the Phase III clinical study is the first to show analgesic efficacy of any twice-daily oxycodone formulation over 12 weeks in a large, well-controlled clinical study.
Shares of Pain Therapeutics (nasdaq: PTIE - news - people ) closed Monday at $9.86, while shares of King Pharmaceuticals (nyse: KG - news - people ) closed at $11.51.

DSE Going Deepest Sad

DSE is dosing following its downwards pipeline to the small capitalised investors. In a research note Stock Mania analyst Shah showed almost all companies are in down trend rally. Among some hot stock ACI, BEXIMCO Ltd., Kaya Cos in commodities sectors are remarkable and he upgraded them as "Buy" saying next week the overall market may peep up including these companies. He mentioned 'Bextex' as a short time basis hot stock especially before 20 August. Avoiding Food and Bank Sectors may be the best market strategy for the small investors. The market may rise at the end of each trading days for these two weeks. Overall market will play bulish defensive, he wrote in his reasearch note.

Pfizer agreed to settle litigation

Pfizer Inc (PFE.N: Quote, Profile, Research, Stock Buzz) said it had agreed to settle litigation related to its cholesterol drug Lipitor with Canadian generic drug maker Apotex Inc. (Reporting by Shah Anaym Kabir).

FDA unexpectedly rejects Schering anesthesia drug

Schering-Plough Corp (nyse: SGP - news - people ) said Friday U.S. regulators had rejected Bridion, its drug to reverse the effects of anesthesia that had been heralded as a breakthrough product by analysts and was unanimously recommended by a federal advisory panel. Shares of Schering-Plough fell 8.5 percent in early trading.The U.S. Food and Drug Administration issued a "not-approvable" letter for the injectable medicine, also known as sugammadex. The agency cited concerns primarily related to "hypersensitivity/allergic reactions" to the product but raised no concerns about its effectiveness, the company said.Schering-Plough did not describe the allergic reactions. In other drugs used to reverse anesthesia, they can range from decreases in blood pressure to increases in heart rate.It was considered one of the most important products from Schering-Plough's $14.5 billion purchase last November of Organon Biosciences. Some analysts estimated it could generate annual sales of up to $1 billion if approved in the United States."We are surprised and disappointed with this action, especially given that sugammadex received a unanimous recommendation for approval by the FDA Advisory Committee on Anesthetics and Life Support in March of this year," Thomas Koestler, Schering-Plough's research chief, said in a statement.The company said it will continue to press for U.S. approval of the drug and is attempting to address safety issues with the FDA.Bridion was approved by the European Commission on Tuesday, following a favorable recommendation last month by its own advisory panel."I am profoundly disappointed because I thought this drug would dramatically improve patient care and safety," said Dr. Ronald Miller, chairman of anesthesia at the University of California, San Francisco, who is a consultant for Schering-Plough."As an anesthesiologist for over 30 years, I thought the allergic reactions, if due to sugammadex, were very mild and not as serious as drugs we currently use, including neostigmine and succinylcholine," Miller said.Deutsche Bank (nyse: DB - news - people ) analyst Barbara Ryan called the Bridion rejection "a very big surprise." She said the FDA appears to have become overly timid following harsh media and congressional criticism of its approval of other drugs later deemed dangerous, including Merck (nyse: MRK - news - people ) & Co's withdrawn Vioxx arthritis drug."It looks like the FDA is in a bunker-down mode, with Congress all over them," Ryan said. "They're taking an extraordinarily cautious approach."Bridion's ability to quickly reduce residual paralysis would make recovery rooms safer -- by more quickly freeing patients from breathing tubes and their inherent potential of causing harm from undetected loss of oxygen, Miller said."And because sugammadex can completely reverse a profound paralysis, it would have allowed more ideal surgical procedures," Miller said.Schering-Plough has been counting on Bridion and other products from the Organon deal to help ensure competitive future earnings growth. The earnings outlook for Schering-Plough has worsened this year, following negative findings for its Vytorin cholesterol fighter in two clinical trials that have hurt sales of the blockbuster product, which is sold in partnership with Merck.Bridion was approved in Europe for reversal of neuromuscular block, or temporary paralysis, induced by the widely used muscle relaxants rocuronium and vecuronium.It was shown in trials to reverse effects of neuromuscular blockade within minutes -- nine to 12 times faster than the standard reversal agent, neostigmine.Neuromuscular blockade is used by anesthesiologists to cause paralysis during surgical procedures, particularly of the abdomen, chest and brain. But patients require breathing tubes until the drugs wear off or are reversed.Edward Jones analyst Linda Bannister said it is unclear whether the FDA will require a special safety trial for Bridion, and how long it would take.In the meantime, despite the rejection of the product, she said Schering-Plough is still poised to have average annual earnings growth of 10 percent over the next five years, assuming that its other important experimental drugs are approved.Unlike rival drugmakers, she said Schering-Plough is not facing the threat of generic competition in coming years for its big products.Company shares fell to $19.25, from a closing price $21.08 on Thursday on the New York Stock Exchange. (Editing by Shah/Stock Analyst.)

Schering-Plough's Q2 income down

Jul 23, 2008 ( Shah's finance Datamonitor via COMTEX) -- SGP Quote Chart News PowerRating -- Schering-Plough has posted a net income of $398 million for the second quarter of 2008, compared with $517 million for the same quarter in 2007.

The company attributed the lower second quarter earnings to the acquisition of biotech group Organon BioSciences.

The company posted net sales of $4.9 billion in the second quarter of 2008, up 55%, compared to $3.18 billion in the second quarter of 2007.
Fred Hassan, chairman and CEO of Schering-Plough, said: "We are very pleased to see another quarter of strong performance and broad-based growth for our company. Through the action agenda we launched in 2003, we were determined to diversify our company and to build a deep Phase III pipeline.
"Today, we are succeeding on both fronts. Our Phase III pipeline is now the strongest in our company's history, and the $16 billion acquisition of Organon BioSciences in November 2007 has already met its accretion target for 2008."

Shah downgraded the company's share sell saying technically in weekly frame chart price recovered from down and met the value line and ready to fall again. He wrote also all the indicators in both type of charts daily frame and weekly frame are negative and intends to move down more. He made his Target price at $ 18.00.

www.stockdselse.blogspot.com

SSL International says Q1 trading in line with its expectations

LONDON, Jul 24, 2008 ( Shah's financial ) -- SLSLF Quote Chart News PowerRating -- SSL International Plc. said its first quarter trading is in line with expectations with good underlying revenue growth, beneficial exchange rate movement and a strong balance sheet.
"Durex and Scholl, continue to make good progress, driving us towards our target of growing operating profit by at least 10 percent again this year," said chairman Gerald Corbett.
In a trading statement, the consumer products manufacturer said its gross margin is being maintained despite input cost inflation and added that it continues to expect at least a constant gross margin on a full-year basis.

Shah upgrded the stock as BUY maaking target price £500 in his research note.

SGP Upgraded by Lehman Brothers as "Overweight"

Schering-Plough opened at $21.8. So far today the stock has hit a low of $21.57 and a high of $21.95. SGP is now trading at $21.90, up 0.52 (2.43%). After hitting a one-year high of $33.40 in October, the stock hit a one-year low of $13.83 in April. SGP shares are rising this morning after an analyst at Lehman Brothers upgraded the stock to "Overweight" from "Equal weight," and lifted his price target to $27 per share from $22. The analyst added that he thinks SGP will see improving sales of its cholesterol drugs, and should benefit from a limited amount of expiring drug patents over the next five years. Technical indicators for SGP are bullish and steady, while S&P gives the stock a neutral 3 Stars (out of 5) Hold rating. If you’re looking for a hedged play on this stock, consider a November bull-put credit spread below the $17.50 range. SGP hasn't been below 17.50 since April. The stock could lose up to 20.0% before this trade runs into trouble.

DSE Rose a Few Chances

In a note analyst Shah wrote that some compaies of DSE made a chance for rittle investors. He upgraded some companies on the besis of technical. He rated AB Bank, BEXIMCO, KYA COS, ACI, AMBEEFRMA, AMCL PRAN, FUWAN FOOD and PADMA CEMENT as BUY for the next 10 trading days.
He comented these are potential trade that can be opened on the following sunday.

All Funds are going under pressure on BD Stocks

All kinds of Fund of DSE and CSE are going under pressure having notice from the two stock exchange that any Fund does not have facility to declare dividend for their share holders. In a press notice DSE and CSE said that there is no scope to declare any dividend by any Fund Company as there is no such evidence in international market. They also said that as all Funds are not industry based or product based Company, hence they do not have ability to declare dividend. Both Stocks of BD hawk the investors to invest safely finding the inner strength of the company.
Analyst Shah DOWNGRADED all kinds of Funds of BD Socks. He mainly kept fucas on Aims 1st and all ICB Funds for around a month. He said in his research note that investors should stand on a ground of safe floor keeping aloof from Aims 1st.

MRK lost agreement of 200 with SGP

30 June Merck & Co and Schering-Plough have decided to withdraw a New Drug Application for a combination tablet of the firms’ big-selling Claritin and Singulair, and are terminating their eight-year respiratory joint venture.

It is not an overly-surprising decision, coming as it does a couple of months after the two companies received a not-approvable letter from the FDA for a proposed fixed combination of SGP’s Claritin (loratadine) and Merck’s Singulair (montelukast) for the treatment of allergic rhinitis symptoms. The respiratory deal was set up in 2000 specifically to develop and sell the combination pill.

As a result SGP expects to receive $105 million from Merck, to be recognised over the remaining three quarters of 2008. The companies also noted that the actions had no impact on their cholesterol joint venture, through which they market the controversial drug Vytorin, a combination of Zetia (ezetimibe) and Zocor.

And in other news that seems good that Merck announced the results of its new study in which its investigational candidate, odanacatib, reduced measures of bone turnover in women with breast cancer that has spread to the bones which were presented at the International Meeting on Cancer Induced Bone Disease.

Analyst Shah downgraded the stock and made his target price $ 34. He suggest the investor to go SHORT from around $ 38.

A Recent view on Helthcare Sectors

A JPMorgan analyst placed "Buy" ratings on shares of Merck & Co. and Schering-Plough Corp. Wednesday, but voiced cautions on the pharmaceutical sector and on shares of other major drug makers. The top issues facing drug makers include a more cautious Food and Drug Administration and a wave of patent expirations on blockbuster drugs over the next few years. Merck is in top pick, as shares should rise as the company builds sales of its diabetes treatment Januvia and its human papillomavirus vaccine Gardasil, along with restructuring efforts that are lowering its costs. Schering-Plough's buyout of Organon Biosciences by $14.5 billion deal that closed in November should allow the company to significantly improve its profit margins. These two companies are also the most protected from a new "patent cliff" under a period where a large number of valuable drugs go off-patent between 2010 and 2012,

JPMorgan gave "Neutral" ratings to Bristol-Myers Squibb Co. and Pfizer Inc. because some of their most important drugs will lose patent protection over the next few years. Wyeth has little to offer beyond its Alzheimer's drug candidate bapineuzumab, and Eli Lilly & Co.'s pipeline consists mostly of early-stage drugs

The sector has also been hit by concerns about the effectiveness of drugs already on the market wrote Shah in his research note.